Eagle Bay Advisors’s Vor Biopharma VOR Stock Holding History

Eagle Bay Advisors’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8	Closed	-$2K	–	1293
2021 Q3	$2K	Buy	+8	New	+$2.38K	﹤0.01%	999

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Eagle Bay Advisors's VOR Position: Q1 2025 in Review

Eagle Bay Advisors sold out of Vor Biopharma (VOR) in Q1 2025, closing a stake of 8 shares — an estimated $167 sold.

Eagle Bay Advisors first reported a position in VOR in Q2 2021 and held it in 13 quarters. The position peaked at $3K in Q2 2021. 46 funds tracked by Wall St. Rank hold VOR as of Q1 2025.

Eagle Bay Advisors reported no remaining Vor Biopharma position as of Q1 2025 after selling out during the quarter.
Eagle Bay Advisors sold 8 Vor Biopharma shares in Q1 2025, an estimated $167.
Eagle Bay Advisors first reported a position in Vor Biopharma in Q2 2021 and held it in 13 quarters.
Eagle Bay Advisors's Vor Biopharma position peaked at $3K in Q2 2021.
46 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2025.

Based on Eagle Bay Advisors's 13F filing for Q1 2025, filed 5 May 2025.